pharmaphorum
JANUARY 28, 2021
It’s important that the biosimilar market continue to build on the success established last year in 2021. Based on this momentum, we’re making three predictions for 2021: we will see increased competition within individual markets pay off, expansion in the biosimilar channel to include new therapeutic categories, and more regulatory support.
Putting Patients First Blog
APRIL 14, 2025
While we recognize CMS intent to strengthen program integrity and reduce fraud, we are deeply concerned that several provisions in this rule will create obstacles to coverage, increase out-of-pocket costs, and disproportionately impact vulnerable populations.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
FEBRUARY 4, 2022
Lilly is a little vague on when it will now file donanemab with the FDA – suggesting on its fourth quarter 2021 results call that it may do so later this year – but reiterated that it has little hope of the drug being used ahead of the readout of TRAILBLAZER-ALZ 2 in mid-2023.
pharmaphorum
APRIL 29, 2021
Officially launched in 2016, Kaia’s technology can now be accessed by 60 million patients worldwide and it claims to be the biggest player in digital MSK in terms of coverage. “Last year saw record investment in digital health and according to a Rock Health report this continued into 2021, with $6.7
Putting Patients First Blog
JANUARY 9, 2025
Medicaid is a critical lifeline for patients and provides insurance for nearly 80 million people across every state in the country. Prevent health insurance premium increases. Since the enhanced APTCs were first enacted in 2021, they have helped 9.4 million Americans gain access to high-quality and affordable health coverage.
Putting Patients First Blog
SEPTEMBER 3, 2024
The NHC appreciates CMS’ efforts to gather patient-centered data as part of this ICR and its commitment to making the process more relevant for patients and patient organizations. While we acknowledge these improvements, it is important to note that some aspects of the data collection process may remain challenging.
pharmaphorum
OCTOBER 1, 2022
In this latest coverage, pharmaphorum speaks with Eugene Borukhovich. Borukhovich is hesitant to compare this year’s conference with the 2021 event. “I If we look at insurers, during the kind of peak of the pandemic, insurers were not paying out, so, there was in theory lots of cash saved up for further investments.
Expert insights. Personalized for you.
119 
Let's personalize your content